Betafectin PGG-Glucan data

ABTI presented full analysis of a Phase I/II trial in 30 patients who had major chest or abdominal surgery, showing a 70 percent reduction in confirmed infections as compared to placebo.

Treated patients also averaged five fewer days in the hospital and three fewer days in intensive care, according to the report at the American College of Surgeons Clinical Conference in San Francisco. No adverse effects were associated with the agent. ...